These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30805315)

  • 21. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.
    Ogbomo H; Zemp FJ; Lun X; Zhang J; Stack D; Rahman MM; McFadden G; Mody CH; Forsyth PA
    PLoS One; 2013; 8(6):e66825. PubMed ID: 23762498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccinia virus outperforms a panel of other poxviruses as a potent oncolytic agent for the control of head and neck squamous cell carcinoma cell lines.
    Nichols AC; Yoo J; Um S; Mundi N; Palma DA; Fung K; Macneil SD; Koropatnick J; Mymryk JS; Barrett JW
    Intervirology; 2014; 57(1):17-22. PubMed ID: 23942307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human SNF5 arming of double-deleted vaccinia virus shows oncolytic and cytostatic activity against central nervous system atypical teratoid/rhabdoid tumor cells.
    Thakur S; Ruan Y; Zhang C; Lun X; Jayanthan A; Narendran A
    Cancer Gene Ther; 2021 Aug; 28(7-8):739-744. PubMed ID: 32678303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
    Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
    PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Oncolytic virus therapy for malignant brain tumors].
    Ino Y; Todo T
    Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.
    Autio K; Knuuttila A; Kipar A; Ahonen M; Parviainen S; Diaconu I; Kanerva A; Hakonen T; Vähä-Koskela M; Hemminki A
    Vet Comp Oncol; 2016 Dec; 14(4):395-408. PubMed ID: 25302859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic properties of non-vaccinia poxviruses.
    Ricordel M; Foloppe J; Pichon C; Findeli A; Tosch C; Cordier P; Cochin S; Quémeneur E; Camus-Bouclainville C; Bertagnoli S; Erbs P
    Oncotarget; 2018 Nov; 9(89):35891-35906. PubMed ID: 30542506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus.
    Guo ZS; Liu Z; Sathaiah M; Wang J; Ravindranathan R; Kim E; Huang S; Kenniston TW; Bell JC; Zeh HJ; Butterfield LH; Gambotto A; Bartlett DL
    Mol Ther Methods Clin Dev; 2017 Dec; 7():112-122. PubMed ID: 29085848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis.
    Ottolino-Perry K; Tang N; Head R; Ng C; Arulanandam R; Angarita FA; Acuna SA; Chen Y; Bell J; Dacosta RS; McCart JA
    Int J Cancer; 2014 Feb; 134(3):717-30. PubMed ID: 23893655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.
    Thirunavukarasu P; Sathaiah M; Gorry MC; O'Malley ME; Ravindranathan R; Austin F; Thorne SH; Guo ZS; Bartlett DL
    Mol Ther; 2013 May; 21(5):1024-33. PubMed ID: 23439499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
    Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
    Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.
    Advani SJ; Buckel L; Chen NG; Scanderbeg DJ; Geissinger U; Zhang Q; Yu YA; Aguilar RJ; Mundt AJ; Szalay AA
    Clin Cancer Res; 2012 May; 18(9):2579-90. PubMed ID: 22379115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular characterization and expression analysis of interleukin 15 (IL15) and interleukin-15 receptor subunit alpha (IL15Rα) in dojo loach (Misgurnus anguillicaudatus): Their salient roles during bacterial, parasitic and fungal infection.
    Chen X; Kong W; Yu Y; Dong S; Huang Z; Yu W; Xu J; Luo Y; Wang Q; Xu Z
    Mol Immunol; 2018 Nov; 103():293-305. PubMed ID: 30343118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development.
    Ho TY; Mealiea D; Okamoto L; Stojdl DF; McCart JA
    Mol Ther Oncolytics; 2021 Sep; 22():85-97. PubMed ID: 34514091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma.
    Christie JD; Appel N; Zhang L; Lowe K; Kilbourne J; Daggett-Vondras J; Elliott N; Lucas AR; Blattman JN; Rahman MM; McFadden G
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiproliferative effects of 111In- or 177Lu-DOTATOC on cells exposed to low multiplicity-of-infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor.
    Akinlolu O; Ottolino-Perry K; McCart JA; Reilly RM
    Cancer Biother Radiopharm; 2010 Jun; 25(3):325-33. PubMed ID: 20578838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective tropism of a neurotropic coronavirus for ependymal cells, neurons, and meningeal cells.
    Tardieu M; Boespflug O; Barbé T
    J Virol; 1986 Nov; 60(2):574-82. PubMed ID: 3021991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor.
    Opgenorth A; Graham K; Nation N; Strayer D; McFadden G
    J Virol; 1992 Aug; 66(8):4720-31. PubMed ID: 1629952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.
    Liu Z; Ravindranathan R; Li J; Kalinski P; Guo ZS; Bartlett DL
    Oncoimmunology; 2016 Mar; 5(3):e1091554. PubMed ID: 27141352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.